west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "B 细胞" 8 results
  • 心脏不停跳手术中心肌NF-κB转录活性、ICAM-1的表达及其临床意义

    目的 探讨心脏不停跳与心脏停搏手术对心肌核转录因子κB(NF-κB)转录活性、细胞间黏附分子-1(ICAM-1)表达水平的影响及其临床意义。方法 将40例先天性心脏病患者随机分为两组,每组20例。组Ⅰ:行心脏不停跳心内直视手术;组Ⅱ:行常规体外循环手术(灌注冷晶体心脏停搏液)。两组患者均于心内操作前、后取右心房壁心肌组织检测NF-κB转录活性、ICAM-1表达水平,用透射电子显微镜观察心肌超微结构;分别于术前、主动脉开放或心内操作完成后1、24、48和72h测定两组心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶MB(CK-MB),并对其结果进行比较。结果术后组Ⅰ NF-κB转录活性、ICAM-1表达水平较术前无显著变化,组Ⅱ NF-κB转录活性较术前升高(Plt;0.01);术后NF-κB转录活性组Ⅱ显著高于组Ⅰ(Plt;0.01)。术后两组血清cTnI、CK-MB水平较术前均有不同程度升高(Plt;0.01),主动脉开放后/心内操作完成后各时点,组Ⅱ均显著高于组Ⅰ(Plt;0.01)。透射电子显微镜观察,组Ⅰ术后心肌超微结构无明显变化,组Ⅱ心肌损伤变化显著。结论 心脏不停跳下心内直视手术术后短期内心肌NF-κB转录活性、ICAM-1表达水平无明显变化,减轻了心肌缺血-再灌注损伤及由NF-κB激活而引起的心肌炎性反应,有较好的心肌保护效果。

    Release date:2016-08-30 06:23 Export PDF Favorites Scan
  • 白细胞介素-21 对 B 细胞信号调节及与系统性红斑狼疮发病机制的研究

    系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种女性多发、累及多器官的慢性难治性自身免疫性疾病。白细胞介素(interleukin,IL)-21 是一种具有多种生物学功能的细胞因子,主要由活化 T 细胞合成与分泌,其受体分布广泛,与 B 细胞表面的 IL-21 受体结合可调控 B 细胞,包含正向促进 B 细胞向浆细胞分化,调节免疫球蛋白产生;反向条件性诱导 B 细胞凋亡及 B10 细胞产生两方面作用。正向作用在于促使 SLE 患者产生自身抗体,而反向作用是促使产生自身抗体的 B 细胞数量减少,而且使 B10 细胞产生更多的具有免疫抑制作用的 IL-10。正反向平衡精准调控有助于对 SLE 病情进行条件性干预,对于疾病的治疗具有重要潜在价值。该文探讨了 IL-21 调控 B 细胞的分化及其与 SLE 之间的关系,对探索 IL-21 对 B 细胞的信号通路在 SLE 发病机制和靶向治疗提供新的思路。

    Release date:2017-12-25 06:02 Export PDF Favorites Scan
  • The interpretation of the Chinese Society of Clinical Oncology clinical guidelines for the diagnosis and treatment of diffuse large B-cell lymphoma

    Diffuse large B-cell lymphoma is highly heterogeneous and is diagnosed according to the 2016 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. The decision of treatment should be upon age, International Prognostic Index score and the tolerability of chemotherapy. High-dose chemotherapy and autologous stem cell transplantation is the standard care for relapsed, chemotherapy sensitive patients. Clinical trials are recommended in specific conditions.

    Release date:2019-04-22 04:14 Export PDF Favorites Scan
  • The management of a patient with primary pancreatic diffuse large B-cell lymphoma by muti-disciplinary term

    ObjectiveTo summarize the individualized diagnosis and treatment experience in a patient with primary pancreatic diffuse large B-cell lymphoma.MethodsBy muti-disciplinary term (MDT) model, a patient with primary pancreatic diffuse large B-cell lymphoma admitted in the People’s Hospital of Chishui in Dec. 2016 was discussed. The diagnosis, perioperative period management, and operation scheme were carried out by the MDT.ResultsThe patient’s general condition was good. After multidisciplinary discussion in the Department of Radiology, Oncology, Interventional, and Hepatobiliary and Pancreatic Surgery, the patient was considered to have surgical indications. After thorough communication with the patient and family, the patient was selected for surgical resection. The whole operation lasted for 5 hours, and the intraoperative blood loss was about 300 mL. The operation was successfully completed and no complications such as pancreatic fistula occurred after operation. Liquid drainage tube was drawn out at 10 days after opertion, and pancreatic tube stent and T tube were retained. The patient discharged on 13 days after surgery. Subsequently, the patient underwent adjuvant chemotherapy. At present, the patient has been followed up for 1 year, no signs of tumor recurrence and metastasis, and continued follow-up.ConclusionsPrimary pancreatic diffuse large B-cell lymphoma is rare and has a poor prognosis. The main treatment is mutli-mode treatment based on surgical resection combined with chemotherapy.

    Release date:2019-06-05 04:24 Export PDF Favorites Scan
  • Differences of CD19+IL-10+ B cell and its subsets contents in peripheral blood and cancer tissues of patients with colorectal cancer and its clinical significances

    Objectives To investigate contents and clinical significances of CD19+IL-10+ B cell and its subsets in peripheral blood monouclear cell (PBMC) and cancer tissue of patient with colorectal cancer (CRC). Methods Thirty-eight patients with CRC underwent surgery from November 2017 to November 2018 in this hospital were enrolled as a trail group. The proportions of CD19+IL-10+ B cell, CD19+IL-10+CD24hiCD38hi B cell, CD19+IL-10+CD24intCD38int B cell, and CD19+IL-10+CD24hiCD38– B cell in the CD19+ B cells in the PBMC, cancer tissue and paracancer tissue of these patients were detected by the flow cytometry. Thirty-seven healthy volunteers were selected as a control group and the same cell types same as the trail group were detected by the same method in the PBMC only. Results ① The contents of CD19+IL-10+ B cell and CD19+IL-10+CD24hiCD38hi B cell of the PBMC in the trail group were significantly higher than those in the control group (t=9.09, P<0.01; t=9.36, P<0.01, respectively), which of the cancer tissues in the trail group were significantly higher than those in the corresponding paracancer tissues (t=11.67, P<0.01; t=19.64, P<0.01, respectively), while the content of CD19+IL-10+CD24hiCD38– B cell of the PBMC in the trail group was significantly lower than that in the control group (t=6.15, P<0.01). But the CD19+IL-10+CD24intCD38int B cell had no significant difference of the PBMC between these two groups (t=1.78, P=0.08). ② The contents of CD19+IL-10+ B cell and CD19+IL-10+CD24hiCD38hi B cell of the PBMC in the CRC patients with stage Ⅲ+Ⅳ were significantly higher than those in the CRC patients with stage Ⅰ+Ⅱ (t=5.39, P<0.01; t=3.13, P<0.01, respectively). The others all had no significant differences (P>0.05). Conclusion CD19+IL-10+ B cells are significantly increased in PBMC and cancer tissue of patient with CRC and with advanced CRC (TNM stage Ⅲ+Ⅳ), further more, main increasing subgroup of CD19+IL-10+ B cell is CD19+IL-10+CD24hiCD38hi B cell, which indicates that CD19+IL-10+ B cell and CD19+IL-10+CD24hiCD38hi B cell might participate in tumorigenesis and tumor progress of CRC.

    Release date:2019-06-26 03:20 Export PDF Favorites Scan
  • MDT discussion of a case of primary diffuse large B cell lymphoma of liver

    ObjectiveTo investigate the clinical manifestations, imaging manifestations, etiology, histological origin, pathological characteristics, diagnosis and differential diagnosis, selection of treatment methods, and prognosis of primary diffuse large B cell lymphoma of livers (PDLBCLL), so as to improve understanding and reasonable diagnosis and treatment of this kind of disease.MethodThe clinicopathologic data of a case of PDLBCLL diagnosed in the West China Hospital of Sichuan University in June 2019 were analyzed retrospectively.ResultsIt was very difficult to diagnose PDLBCLL preoperatively and to distinguish PDLBCLL from primary liver cancer and other liver space occupying lesions. It was also easy to ignore the possibility of invasion of liver by lymphopoietic tissue tumor, which was often diagnosed by postoperative pathological diagnosis or puncture biopsy, and after the elimination of hematological diseases by various examinations. This patient was admitted to the hospital as a space occupying in right liver. Preoperative imaging examination considered that may be a tumor. After MDT discussion, considering that the nature of the tumor should be confirmed by surgical resection, and then go to the Department of Oncology. Irregular right hemihepatectomy + cholecystectomy + hilar lymphadenectomy + diaphragmatic repair was performed after MDT discussion. The diagnosis of PDLBCLL was confirmed by postoperative pathological examination. The operation duration was about 230 min, and the intraoperative blood loss was about 200 mL. The patient recovered well without complications and was discharged on the 10th day after operation. The patient was followed up for 9 months. The liver and kidney function, electrolytes and abdominal Doppler ultrasound examination were regularly reviewed every month. No obvious abnormality was found in these results.ConclusionsAt present, there is no unified treatment principle, most of them will undergo surgery, chemotherapy, radiotherapy or combined treatment. Due to its unknown etiology and unclear mechanism, clinicians can only implement individualized treatment according to the characteristics of patients’ conditions.

    Release date:2021-02-08 07:10 Export PDF Favorites Scan
  • Expression and clinical significance of immune cell subsets in elderly patients with primary immune thrombocytopenia

    Objective To investigate the expression and clinical significance of T lymphocyte subsets, natural killer (NK) cells and CD19+ B cells in the elderly with primary immune thrombocytopenia (ITP) before and after treatment. Methods The elderly ITP patients diagnosed and treated in the Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine (preparatory stage) between January 2014 and June 2019 were retrospectively selected as the observation group. The healthy elderly in the same period were selected as the control group. According to the treatment, the observation group was divided into effective group and ineffective group. The expression levels of T lymphocyte subsets (CD3+, CD4+, CD8+ and CD4+/CD8+), NK cells and CD19+ B cells were observed and analyzed. Results A total of 75 subjects were included, including 35 in the observation group and 40 in the control group. The total effective rate was 85.71% (30/35). Before treatment, the expression levels of T lymphocyte subsets (CD3+, CD4+ and CD4+/CD8+) in the observation group were lower than those in the control group (P<0.05). There was no significant difference in other indexes between the two groups (P>0.05). After treatment, except for CD8+, the expression levels of T lymphocyte subsets (CD3+, CD4+ and CD4+/CD8+) in the observation group were higher than those before treatment (P<0.05). The expression levels of NK cells and CD19+ B cells were lower than those before treatment (P<0.05). The expression levels of T lymphocyte subsets (CD3+, CD4+ and CD4+/CD8+) in the effective group were higher than those before treatment (P<0.05), while the expression level of CD19+ B cells was lower than that before treatment (P<0.05). There was no significant difference in other indexes before and after treatment (P>0.05). There was no significant difference in the expression levels of T lymphocyte subsets (CD3+, CD4+, CD8+ and CD4+/CD8+), NK cells and CD19+ B cells in the ineffective group before and after treatment (P>0.05). Conclusions T lymphocyte subsets are abnormal in elderly ITP patients. The immune abnormality of T lymphocyte may be one of the reasons for elderly patients with ITP. With the improvement of therapeutic effect, immune cell subsets have also been improved.

    Release date: Export PDF Favorites Scan
  • Interferon regulatory factor 4 involvement in the pathogenesis and development of B cell or plasma cell tumors: an update of research progresses

    Interferon regulatory factor 4 (IRF4) is one of the transcription factors in the interferon regulatory factor family. In the normal physiological process, IRF4 protein is a key factor regulating B cell development, such as early B cell development, pre-B cell switch recombination, mature B cell somatic hypermutation, and also a key factor regulating plasma cell differentiation. In addition, in recent years, it has been reported that Irf4 gene abnormalities or abnormal protein expression is closely involved in the occurrence and development of a variety of B cell or plasma cell tumors. This article reviews the physiological role of IRF4 in the differentiation and maturation of B cell or plasma cells, how IRF4 participates in the occurrence and development of B cell or plasma cell tumors, and its potential therapeutic target for B cell or plasma cell tumors.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content